A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease

Trial Profile

A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Meniere's disease
  • Focus Adverse reactions
  • Sponsors Otonomy
  • Most Recent Events

    • 13 Sep 2017 According to an Otonomy media release, all development activities for OTIVIDEX have been suspended including termination of ongoing clinical trials and pre-registration support efforts.
    • 13 Sep 2017 Status changed from active, no longer recruiting to discontinued according to an Otonomy media release.
    • 16 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top